GLP1R and type 2 diabetes mellitus: Furthermore, aberrant Mfn2 expression has been reported in metabolic disorders, including type 2 diabetes mellitus and insulin resistance [73], for which Exenatide and GLP-1R agonists are effective in treatments [76].